PETRARCA, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 1.774
EU - Europa 1.031
AS - Asia 237
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.056
Nazione #
US - Stati Uniti d'America 1.771
RU - Federazione Russa 415
SE - Svezia 144
PL - Polonia 134
IE - Irlanda 123
CN - Cina 74
HK - Hong Kong 67
SG - Singapore 62
IT - Italia 54
DE - Germania 48
UA - Ucraina 37
FI - Finlandia 30
GB - Regno Unito 26
TR - Turchia 13
IN - India 12
CI - Costa d'Avorio 11
BE - Belgio 10
JO - Giordania 7
CZ - Repubblica Ceca 4
NL - Olanda 3
CA - Canada 2
CH - Svizzera 2
EU - Europa 2
VN - Vietnam 2
FR - Francia 1
MX - Messico 1
SC - Seychelles 1
Totale 3.056
Città #
Santa Clara 284
Fairfield 193
Chandler 164
Warsaw 134
Dublin 123
Ashburn 122
Wilmington 88
Seattle 87
Cambridge 85
Ann Arbor 83
Woodbridge 79
Jacksonville 64
Houston 58
Singapore 48
Beijing 43
Hong Kong 42
Boardman 31
Princeton 30
Buffalo 28
Boston 23
Bremen 23
Altamura 22
Lawrence 20
San Diego 15
Shanghai 14
Izmir 12
Mumbai 12
Abidjan 11
Falls Church 11
Medford 11
Brussels 10
Andover 6
Norwalk 5
Brno 4
New York 4
Old Bridge 4
Washington 4
Ferriere 3
Montalbano Jonico 3
Moscow 3
Bern 2
Dong Ket 2
Florence 2
Hillsboro 2
Kent 2
London 2
Los Angeles 2
Padova 2
Toronto 2
West Jordan 2
Auburn Hills 1
Brescia 1
Brooklyn 1
Chieti 1
Frankfurt Am Main 1
Genoa 1
Grevenbroich 1
Groningen 1
Hangzhou 1
Laurel 1
Leawood 1
Luoyang 1
Mérida 1
Nanjing 1
Phoenix 1
Portland 1
Redmond 1
Salerno 1
San Mateo 1
St Petersburg 1
Tappahannock 1
Terni 1
Verona 1
Xi'an 1
Yubileyny 1
Totale 2.051
Nome #
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 225
Acute viral hepatitis increases liver stiffness values measured by transient elastography 155
Host genetic determinants in HCV-related mixed cryoglobulinemia 143
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 141
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 141
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 140
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C 132
Host genetic determinants in HCV-related mixed cryoglobulinemia 125
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 123
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 121
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 118
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 110
Transient elastography (TE) is more effective for the identification of HCV patients with advanced (F3-F4) rather than significant (F2-F4) liver fibrosis 106
Analysis of HCV persistence in patients with sustained virological response 105
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 104
Host genetic determinants in HCV-related mixed cryoglobulinemia 102
Transient elastography (TE) is more effective for the identification of HCV patients with severe (> F3) rather than significant (> F2) liver fibrosis 98
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 94
Behaviour of sustained responders to anti-HCV treatment: may HCV infection be eradicated? 84
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 77
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 72
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 69
Can depletion of B-cells by anti-CD20 monoclonal antibody in HCV plus mixed cryoglobulinemia (MC) improve liver cirrhosis? 65
IL28B polymorphism as predictor of response to anti-HCV terapy in HCV-related mixed cryoglobulinemia syndrome 65
Effect of rituximab on advanced liver disease in patients with HCV-related mixed cryoglobulinemia. 63
Effects of depletion of B cell by anti-CD20 monoclonal antibody in HCV+ mixed cryoglobulinemia (MC) and liver cirrhosis 62
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 62
Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia 61
L'epatite B: un problema antico di rinnovata attualità 50
Utilizzo del Rituximab (Anticorpo Monoclonale anti-CD20) nel Trattamento dei Pazienti con Sindrome Crioglobulinemica HCV-correlata e Malattia Epatica Avanzata 46
Totale 3.059
Categoria #
all - tutte 8.258
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.258


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020354 0 0 0 0 45 53 46 56 53 50 45 6
2020/2021262 29 15 27 22 6 34 9 22 24 33 24 17
2021/2022237 7 31 4 10 13 9 11 15 11 5 51 70
2022/2023621 53 69 35 68 64 115 75 41 82 4 13 2
2023/2024192 14 23 32 15 9 31 5 53 2 2 2 4
2024/2025892 64 150 94 226 358 0 0 0 0 0 0 0
Totale 3.059